News

CN Bio Innovations announces research collaboration with AstraZeneca to validate a new in vitro tool to predict optimised drug dosing regimens for multi-drug therapies

London, UK, November 1 2017: Organ-on-a-Chip specialist CN Bio Innovations Limited announces a research collaboration with global biopharmaceutical company AstraZeneca to validate a new in vitro research tool that enables the high throughput evaluation of multi-drug dosing regimens. Under the collaboration, CN Bio will leverage intellectual property and technologies recently licensed by the company from… Read more »

READ MORE

FDA signs collaborative agreement with CN Bio Innovations to use Organs-on-Chips to improve drug development and evaluation

London, UK, October 26 2017: CN Bio Innovations Limited announced today that it has entered into a Research Collaboration Agreement with the US Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research. FDA and CN Bio will collaborate to characterize the performance of CN Bio’s Organs-on-Chips as a platform for potential use in… Read more »

READ MORE

Innovate UK awards grant to CN Bio Innovations and AstraZeneca to use Organs-on-Chips to evaluate the use of existing drugs to treat fatty liver disease

London, UK, October 11 2017: Organ-on-a-Chip specialist CN Bio Innovations Limited announces that Innovate UK has awarded the company a £670,000 grant co-funded by the newly created Industrial Strategy Challenge Fund. Under the award, CN Bio will collaborate with global biopharmaceutical company AstraZeneca to combine Organ-on-a-Chip models of fatty liver disease and non-alcoholic steatohepatitis (NASH)… Read more »

READ MORE

CN Bio Innovations announces licence of platform microfluidics technologies from Vanderbilt University

London, UK, October 10 2017: CN Bio Innovations Limited announces that it has licensed from Vanderbilt University three patents and applications, and software, covering microfluidics technologies relevant to the company’s Organs-on-Chips products and IP portfolio. The agreement includes exclusive rights to applications claiming priority from US 15/191,092, as well as non-exclusive rights to US 9,618,129… Read more »

READ MORE

CN Bio Innovations announces license of worldwide rights to Hepatitis B programme from Bristol-Myers Squibb

London, UK, April 5 2017: CN Bio Innovations Limited announces that it has licensed from Bristol-Myers Squibb Company a Hepatitis B drug discovery programme comprising several series of small molecule antiviral compounds. The exclusive agreement enables CN Bio to undertake discovery, development and commercialisation of the antiviral compounds to create a combination treatment for chronic Hepatitis… Read more »

READ MORE

Huffington Post features CN Bio

Huffington Post features CN Bio CEO: Women in Innovation: Developing ‘Organs-on-Chips’ Interview clip: “My background as a chemist means that I like precision. However, drug development is not nearly as logical as we’d like. Profound uncertainty about the likely success of drug programs can persist into late stage clinical trials – by which time millions… Read more »

READ MORE

CN Bio featured on the Discovery Channel

Discovery Channel features CN Bio’s human-organ-on-a-chip platforms “Innovations” on the Discovery Channel has reported on CN Bio Innovations’ technology which allows drug discovery scientists to understand with greater precision than ever before whether a new drug candidate is likely to be safe and effective. “Innovations” is hosted by Ed Begley Jr, and the CN Bio… Read more »

READ MORE

Dr Emma Sceats of organ-on-a-chip firm CN Bio Innovations wins Innovate UK’s infocus Women in Innovation award

Welwyn Garden City, UK- 15th November 2016: Following a nationwide competition, CEO of London bioengineering firm CN Bio Innovations Dr Emma Sceats has been named as a winner of Innovate UK’s infocus Women in Innovation award. The awards will be celebrated as part of the Lloyds National Business Awards in London tonight. Innovate UK’s infocus… Read more »

READ MORE

MIT and CN Bio to showcase world’s first 7 organ “Human-on-a-Chip” at Organ-On-Chip congress

MIT and CN Bio Innovations today announced that the world’s first 7-organ “Human-on-a-Chip” platform will be showcased at the Organ-on-Chip congress in Boston on the 7th and 8th of July 2016. Under a $26M Defense Advanced Research Projects Agency (DARPA) contract awarded to researchers at the Massachusetts Institute of Technology, Continuum LLC and CN Bio… Read more »

READ MORE

CN Bio Sponsors the Organ-On-Chip world congress in Boston

CN Bio Innovations Ltd, an expert in developing human organs-on-chips to test and develop therapeutics for serious diseases, is proud to be the platinum sponsor of SelectBio’s 2nd Annual Organ-on-a-Chip world Congress in Boston on the 7th and 8th of July. The conference brings together the world’s leading experts in Organ-on-chip technology from academia and… Read more »

READ MORE

CN Bio appoints Emma Sceats as CEO

CN Bio Innovations are delighted to announce the appointment of Dr Emma Sceats as Chief Executive effective 1st January 2016. Dr David Scales will remain on the board as an advisor to the company with particular emphasis on new business opportunities.

READ MORE

Imperial College London to present HBV data on CN Bio immune-competent liver model at AASLD The Liver Meeting

CN Bio Innovations Ltd, an expert in developing human organ chip platforms to test and develop therapeutics for serious diseases, has announced that new data from its research collaboration with Imperial College London, where the team are analysing a novel human, full-viral-lifecycle model of Hepatitis B, will be presented in the late-breaking poster session at The Liver Meeting® 2015, San Francisco USA (13-17 November, 2015).

READ MORE

CN Bio appoints Dr David Hughes to board of directors

Dr David Hughes has been appointed to the board of directors, effective immediately. He will also continue with his responsibility for overseeing management of all technical projects and alliances with CN Bio partners as well as managing the internal scientific and engineering teams.

READ MORE

Al Jazeera

CN Bio Innovations features in Al Jazeera documentary “The Cure”.

READ MORE

CN Bio Innovations announces deal with sixth pharmaceutical collaborator in 2015 and features in The Economist

CN Bio Innovations, an expert in developing human organ-on-a-chip platforms to test and develop therapeutics for liver diseases and infection, is featured prominently in an article in the 13 June 2015 edition of The Economist. Simultaneous with the publication, CN Bio is pleased to announce that it has embarked on a joint research collaboration with a sixth pharmaceutical company since March 2015. The research will be based on CN Bio’s Quantum-B® model of Hepatitis B infection and leverage CN Bio’s expertise in cell culture and disease modelling.

READ MORE

CN Bio Innovations announces research collaboration with Alnylam

CN Bio Innovations, an expert in developing human organ-on-a-chip platforms to test and develop therapeutics for liver diseases and infection, is pleased to announce the commencement of a research collaboration with Alnylam Pharmaceuticals. Research relevant to the advancement of Alnylam’s RNAi therapeutics will be performed using CN Bio’s human liver-on-a-chip platform, LiverChip.

READ MORE

CN Bio Innovations announces LiverChip research study with leading pharmaceutical company

CN Bio Innovations, an expert in developing human organ-on-a-chip platforms to test and develop therapeutics for liver diseases and infection, is pleased to announce the commencement of a research study with a fourth pharmaceutical company.

The program will take advantage of CN Bio’s human liver-on-a-chip platform, LiverChip, to study targets implicated in liver disease.

READ MORE